
Sign up to save your podcasts
Or
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
4.8
168168 ratings
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
322 Listeners
496 Listeners
58 Listeners
272 Listeners
3,321 Listeners
1,081 Listeners
194 Listeners
43 Listeners
514 Listeners
321 Listeners
243 Listeners
105 Listeners
53 Listeners
363 Listeners
38 Listeners